Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Pharmaceutical Law Removes Incentives For Orphan Drug R&D

This article was originally published in The Pink Sheet Daily

Executive Summary

National biotechnology and pharmaceutical industry associations object to certain provisions in the proposed German law on restructuring the pharma sector, AMNOG, that would add health technology assessments for orphan drugs.

You may also be interested in...



Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs

The new government directive on pricing and reimbursement leaves industry fearing that reference prices will be added to Sweden's value-based pricing system to cut costs.

Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs

The new government directive on pricing and reimbursement leaves industry fearing that reference prices will be added to Sweden's value-based pricing system to cut costs.

New German Reimbursement Process Splits Opinion Ahead Of First Assessments

Several drug firms – including, most vociferously, Eli Lilly & Co. – have already concluded that Germany's tough new reimbursement laws are the root of much evil. But others are taking more of a wait-and-see approach to the new system, which demands that companies provide compelling proof, upfront, of the added benefit of their drugs over existing therapies.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel